Kura Oncology’s (KURA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research report sent to investors on Tuesday,Benzinga reports. The brokerage currently has a $40.00 target price on the stock.

Other equities research analysts also recently issued reports about the stock. Wedbush reiterated an “outperform” rating and set a $38.00 price target (up from $36.00) on shares of Kura Oncology in a report on Friday, November 14th. JMP Securities reaffirmed a “market outperform” rating and issued a $24.00 target price on shares of Kura Oncology in a research note on Monday, October 20th. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a report on Friday, December 5th. UBS Group raised their price objective on Kura Oncology from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, November 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research report on Wednesday, October 8th. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $28.00.

Kura Oncology Stock Performance

NASDAQ KURA opened at $8.91 on Tuesday. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 0.02. Kura Oncology has a fifty-two week low of $5.41 and a fifty-two week high of $12.49. The business has a fifty day moving average of $10.66 and a 200-day moving average of $8.86. The stock has a market cap of $775.35 million, a price-to-earnings ratio of -3.59 and a beta of 0.25.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%. The company had revenue of $20.75 million for the quarter, compared to analyst estimates of $17.48 million. As a group, analysts predict that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Mollie Leoni sold 15,485 shares of the business’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $11.18, for a total transaction of $173,122.30. Following the completion of the sale, the insider owned 225,454 shares in the company, valued at approximately $2,520,575.72. The trade was a 6.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Thomas James Doyle sold 4,539 shares of the stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $11.18, for a total transaction of $50,746.02. Following the sale, the senior vice president directly owned 130,257 shares of the company’s stock, valued at approximately $1,456,273.26. This trade represents a 3.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 68,343 shares of company stock valued at $730,858 in the last 90 days. 6.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Kura Oncology by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock valued at $333,000 after acquiring an additional 2,977 shares during the period. Acadian Asset Management LLC acquired a new stake in Kura Oncology in the 1st quarter valued at $2,180,000. Strs Ohio purchased a new position in Kura Oncology in the first quarter valued at about $143,000. Rhumbline Advisers lifted its stake in shares of Kura Oncology by 5.2% during the first quarter. Rhumbline Advisers now owns 105,206 shares of the company’s stock worth $694,000 after purchasing an additional 5,215 shares in the last quarter. Finally, Harbor Capital Advisors Inc. lifted its stake in shares of Kura Oncology by 23.9% during the second quarter. Harbor Capital Advisors Inc. now owns 47,013 shares of the company’s stock worth $271,000 after purchasing an additional 9,069 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.